TG Therapeutics (TGTX) Stock Analysis & AI Equity Report
TG Therapeutics (TGTX) overview
TG Therapeutics (TGTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 616m and operating profit of USD 123m; the year-end share price was 29.81 USD and market capitalisation was USD 4,630m. TG Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get TG Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About TG Therapeutics
TG Therapeutics is a commercial-stage biotechnology company focused on acquiring, developing and commercializing treatments for B-cell diseases. Its approved medicine BRIUMVI is an infusion for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The company markets BRIUMVI in the United States and works with a partner on commercialization elsewhere.
Generate the TG Therapeutics report
TG Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for TG Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on TG Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.